Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
15 avr. 2019 09h00 HE
|
Aptevo Therapeutics Inc.
Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and...
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
02 avr. 2019 09h02 HE
|
Aptevo Therapeutics Inc.
APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and...
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
25 mars 2019 09h02 HE
|
Aptevo Therapeutics Inc.
SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
20 mars 2019 09h02 HE
|
Aptevo Therapeutics Inc.
Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 ...
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
18 mars 2019 09h00 HE
|
Aptevo Therapeutics Inc.
Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and...
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
07 mars 2019 09h13 HE
|
Aptevo Therapeutics Inc.
SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
06 mars 2019 16h37 HE
|
Aptevo Therapeutics Inc.
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
Aptevo Therapeutics Highlights Key 2019 Priorities
07 janv. 2019 08h30 HE
|
Aptevo Therapeutics Inc.
ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;APVO210 Beginning Phase 1 Clinical Trial in...
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
03 janv. 2019 09h02 HE
|
Aptevo Therapeutics Inc.
SEATTLE, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it...
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
21 déc. 2018 09h00 HE
|
Aptevo Therapeutics Inc.
Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a...